not really - preclinical data showed a nuke (much like interferon) can suppress resistance to PIs. heck - even a nuke as monotherapy did not yeild resistant variants at 2 weeks in the clinic what will be interesting down the road is to see if there is viral rebound once regimens lacking one or both components of soc is eliminated after completing a full course of treatment (note that none of the inform trials are examining this as all are being rolled over to soc immediately following STATC therapy)
Market Data 
Markets 
AI
